Gordon Chang: China’s Communist Regime ‘Happy to Kill

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
99
Gordon Chang: China’s Communist Regime
‘Happy to Kill Tens of Thousands of Americans’
via Fentanyl < >

fentanyl-heroin-getty-640x480.jpg

China’s Communist Party is “very happy to kill tens of thousands of Americans each year” with its fentanyl exports, knowing of overdoses related to the opiate’s abuse, said Gordon Chang, Daily Beast columnist and expert on China, in a Thursday interview on SiriusXM’s Breitbart News Tonight with hosts Rebecca Mansour and Joel Pollak.

Pollak asked Chang about China’s stated commitment to restrict manufacturing and exporting of fentanyl to the U.S., following President Donald Trump’s request for cooperation from Chinese President Xi Jinping on the matter.

Chang replied, “The fentanyl comes from Chinese sources, and these are well-organized gangs. In the semi-totalitarian state that Beijing runs, the Communist Party knows what’s going on. Trump was right to call the Chinese out on this, and the fact that Beijing didn’t do anything about it is a real indication that they were very happy to kill tens of thousands of Americans each year, which means that we should be very happy not to do business with China and close our markets to China, and disengage our economy from them, and give them as rough a time as they’ve been giving us.”

LISTEN:

Chang continued, “What is it going to take to get them to stop fentanyl? I actually don’t know if there is anything. There’s going to be a point where we’re going to have to push the Chinese [Communist Party] to the edge of extinction, and then maybe they will come around, but maybe not.”

On Thursday, Trump announced that his administration would impose a ten percent tariff on the $300 billion of imports from China that have not yet been subject to new import duties, beginning in September.

“This is a great day for the United States of America,” said Chang of Trump’s promise to levy additional tariffs on Chinese imports. “First of all, Chinese leaders are used to deference from their American counterparts, and Trump absolutely showed Xi Jinping that the United States is just not going to bow down to Beijing. A lot of people said Trump is not going to do this, to oppose the additional tariffs on the remaining $300 billion of goods. They were saying consumers would complain, that Trump is too worried about the stock market, that Trump needs a trade deal for the November 2020 elections. Well, the President of the United States showed that everybody was wrong. He certainly surprised me [by] doing this.”

Chang added, “What [Donald Trump] did was show that the United States has that one element that we were concerned about, and that is political will. President Trump exhibited political will today, and that’s a great thing.”

Trump must suffocate Huawei, a China-based telecommunications company linked to the Chinese Communist Party, to protect America’s national security interests, determined Chang.

“I hope, now, that President Trump is not going to give the Chinese the reprieves on Huawei,” expressed Chang, “because that would not be good for us,” adding, “there is a chance that we will not help Huawei” in order to not “rescue that company.”

America must broadly begin decoupling its economy from China’s, advised Chang.

“[America needs] further disengagement from China,” Chang said. “Companies are going to take their supply chains and move them elsewhere because although they can price in additional tariffs, what they can’t price in is the uncertainty. And right now, given the friction between Washington and Beijing, they don’t know where this is going, so they cannot actually make plans, which means it’s much easier for them to move their factories to Vietnam, Bangladesh, or Jordan — wherever. But I think that we’re going to see this disentangling, which is a good thing for us.”

Chang went on, “Given all the other frictions in the relationship, I believe that we are headed for a divorce, which is a good thing, because for too long, the Chinese have been taking advantage of Americans, putting American workers out of work, and all the rest of it, stealing our intellectual property — this has just got to end.”

“We can affect a separation,” added Chang. “It’s going to be painful, but we can’t think that we have done decades of misguided trade policy and think that we can get out of this without cost.”

Pollak asked Chang about potential harm to American consumers in the context of tariff implementation on Chinese imports, noting the phenomenon of comparative advantage in the context of international trade.

“The Chinese don’t believe in the doctrine of comparative advantage, the notion which underpins all of global trade,” responded Chang. “I don’t see how you can run a global trading system with a large trading partner that doesn’t believe in this fundamental, comprehensive notion. We’re going to have to go in a different direction. We can trade with other countries. There are other countries in the world, and there are other countries in the world that are not headed to a debt crisis. So I’m very happy not to have American banks participating in the world’s next big crisis. I think we’re in a good place, right now.”

Chang praised Trump’s foreign policy toward China.

“I actually think that, with regard to the China tariffs, Trump is probably about the only person who could’ve done it,” estimated Chang. “Or let me put it this way: he was the only person who would’ve moved this fast. I think any American president would’ve eventually gotten to where we are today, it just would’ve taken a year and a half to two years, and of course, right now, time is everything, so it’s important. I think the president deserves a lot of credit for what he’s been doing with regard to trade with China.”

Pollak also asked Chang about a potential military conflict between the U.S. and China.

Chang replied, “Samuel Huntington, in Clash of Civilizations, his great work, said that trade is tot necessarily a way to prevent conflict. He said as trade relations deteriorate, then the possibility of military conflict rises fast. So it’s not necessarily the level of trade you have with another country, it’s the direction, and clearly, we are in a way of delinking.”

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DraftKings Faces Revenue Cutback; Legal Probe Begins

Updated Category News Views 103

DraftKings' Surprising Turn of Fortune Talk about a gut punch! DraftKings (NASDAQ: DKNG) dropped a bombshell that had investors reeling. They decided to lop off a hefty slice of their revenue guidance, and trust me, those aren't small numbers we’re talking about. On November 6, they yanked their full-year 2026 revenue guidance down to $6.35 billion to $6.55 billion from...

Continue Reading
Andersen's Window Revamp: Addressing Demand Surge

Updated Category News Views 96

Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...

Continue Reading
Tenax Therapeutics Faces Legal Heat After Stock Plunge

Updated Category News Views 92

Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...

Continue Reading
212NYC Gala Celebrates Ad Industry's Human Touch

Updated Category News Views 157

The Advertising Gala with Heart When you toss nearly 300 advertising honchos into a room at Tribeca's Rooftop, you don't just get another bash; you get an industry checkpoint. This time, the 212NYC shindig on November 5, 2026, wasn't just about stroking egos. It was about spotlighting the soul in business, right when AI threatens to run wild with it. Navigating AI's...

Continue Reading
Pete Crow-Armstrong Unveils Signature Baseball Gloves

Updated Category News Views 83

The Windy City Meets the Diamond Alright, bear with me here. Monday morning vibes, right? But here's something that'll turn your breakfast around if you're into baseball—or just the latest scoop on players making waves in gear. Pete Crow-Armstrong, the Chicago Cubs center fielder who's been lighting up the field, has his name on some fresh gear. We're talking signature...

Continue Reading
PAC Criticizes JD Vance's Billionaire Connections

Updated Category News Views 107

Unveiling Vance's High-Powered Backers Brace yourself for a fresh round of political sparring, folks. The Patriots for American Principles PAC has decided that JD Vance's relationships with the billionaire elite need a little more sunshine. And they're not shy about it—Vance's billionaires will be paraded around the streets of Washington D.C. on a mobile billboard,...

Continue Reading
Koppers Navigates Q3: Margins Squeeze Amid Growth

Updated Category News Views 123

Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...

Continue Reading
Precision Biologics Unveils Promising Data on PB-223

Updated Category News Views 95

Precision's Big Reveal at SITC 2026 When it comes to the shifting tides of oncology advancements, Precision Biologics is making some serious waves. They're not leaning back; they're diving right in with their latest showcase at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2026. CEO Dr. Philip M. Arlen announced compelling preclinical data for their...

Continue Reading
Everest Group Faces Class Action: Key Investor Moves

Updated Category News Views 117

Everest Group's Legal Spiral: What's Happening? Folks, when a company feels like it's caught in an endless storm, investors better hold on tight. That's the situation Everest Group, Ltd. finds itself in, with an 11.4% stock dive that’s got investors reeling. Securities fraud allegations are rocking Everest like a hurricane, and The Law Offices of Frank R. Cruz have put...

Continue Reading
OncoC4's Cesalatamig: Promising Results in NSCLC Trials

Updated Category News Views 85

Hope in Persistence: Cesalatamig in the Spotlight Swinging through the medical landscape like a seasoned fighter, OncoC4's recent revelations at the SITC 2026 give investors and doctors a reason to pay close attention. We're sizing up their investigational drug, cesalatamig, which flaunts a solid objective response rate of 33% among non-small cell lung cancer (NSCLC)...

Continue Reading

Top 5 Most Recently Viewed Articles

Shipley Donuts Expands to Vienna, Delight in Every Bite

Updated Category News Views 73

Shipley Donuts: A Sweet Texas Tradition Lands in Virginia The donut world just got a little tastier in Northern Virginia as Shipley Donuts, that iconic Texan sweetheart, opened shop in Vienna. We're talking handmade donuts, done the old-school way, with a taste that makes you wanna grab a dozen before work. They’ve been crafting this magic for nearly a century, starting...

Continue Reading
Volato's Strategic Expansion with Gulfstream G280 Deliveries

Updated Category News Views 224

Volato's Exciting Addition to Its Fleet Volato Group, Inc. (the "Company" or "Volato") (NYSE American: SOAR), a frontrunner in private aviation, is thrilled to announce a significant milestone: the delivery of its second Gulfstream G280 is set for January 2025. This delivery is part of a strategic order of four aircraft and underscores the company’s proactive approach...

Continue Reading
Velico's Partnership with South Texas Blood Center Revolutionizes Plasma Access

Updated Category News Views 355

Transforming Plasma Access with Innovative Technology In a historic move, the South Texas Blood and Tissue Center (STBT) has become the first civilian blood center in the U.S. to adopt Velico, Inc.'s revolutionary FrontlineODP™ system. This groundbreaking partnership aims to enhance emergency medical practices by providing on-demand spray-dried plasma, making...

Continue Reading
The Incredible Growth of Teradyne: A Decade of Investment

Updated Category News Views 119

Investing in Teradyne: A Decade of Incredible Returns When it comes to long-term investments, certain stocks have consistently proven their worth. Teradyne (NASDAQ: TER) is one such company that has outperformed market expectations over the past decade. With an impressive annualized performance exceeding 11.62%, Teradyne has become a staple in many investors' portfolios....

Continue Reading
Grid Battery Metals Expands Copper Portfolio for Future Growth

Updated Category News Views 126

Grid Battery Metals' Exciting New Copper Acquisition Grid Battery Metals Inc. has made a significant move by acquiring a new copper project, broadening its portfolio in the battery metals sector. Tim Fernback, the President and CEO, articulated the strategic importance of this acquisition and its implications for future exploration activities. Strategic Location of the...

Continue Reading